BEDFORD, Mass.--(BUSINESS WIRE)--Jan. 23, 2017--
Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced today that it has
commenced a registered underwritten public offering of $25 million of
shares of its common stock pursuant to a shelf registration statement
that was previously filed with and declared effective by the Securities
and Exchange Commission (SEC). All of the shares in the offering are to
be sold by the Company.
Cantor Fitzgerald & Co. is acting as the sole bookrunner for the
offering.
Before investing in the offering, interested parties may read the
prospectus supplement and the accompanying prospectus for the offering
and the other documents the Company has filed with the SEC, which are
incorporated by reference in the prospectus supplement and the
accompanying prospectus for the offering and provide more complete
information about the Company and the offering. An electronic copy of
the preliminary prospectus supplement and the accompanying prospectus
for the offering will be available on the website of the SEC at www.sec.gov.
Copies of the preliminary prospectus supplement and the final prospectus
supplement, when available, and the accompanying prospectus relating to
this offering may be obtained by contacting Cantor Fitzgerald & Co.,
Attn: Capital Markets, 499 Park Ave., 5th Floor, New York, New York
10022, or by telephone at 212-829-7122, or by e-mail at prospectus@cantor.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of these
securities, in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful, prior to registration or
qualification under the securities laws of any such state or
jurisdiction. Offers will be made only by means of a prospectus
supplement and the accompanying prospectus, forming a part of the
registration statement.
About Ocular Therapeutix
Ocular Therapeutix, Inc. is a
biopharmaceutical company focused on the development and
commercialization of innovative therapies for diseases and conditions of
the eye using its proprietary hydrogel platform technology. Ocular
Therapeutix has resubmitted a new drug application (NDA) for
post-surgical pain for its lead product candidate, DEXTENZA, which has
completed Phase 3 clinical development for post-surgical ocular
inflammation and pain. Subject to the approval of the NDA for
post-surgical ocular pain, Ocular Therapeutix intends to submit a
supplemental NDA for DEXTENZA to broaden its label to include an
indication for post-surgical inflammation. DEXTENZA is also in Phase 3
clinical development for allergic conjunctivitis. OTX-TP is in Phase 3
clinical development for glaucoma and ocular hypertension. Ocular
Therapeutix is also evaluating injectable drug delivery depots for
back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure®
Sealant, is FDA-approved to seal corneal incisions following cataract
surgery.
Forward Looking Statements
Any statements in this press
release about future expectations, plans and prospects for the Company
including the development and regulatory status of the Company’s product
candidates, such as the Company’s expectations and plans regarding
regulatory submissions for and the timing and conduct of clinical trials
of DEXTENZA for the treatment of post-surgical ocular inflammation and
pain, including the Company’s expectations regarding the NDA filed with
the FDA and the resubmission of the NDA, DEXTENZA for the treatment of
allergic conjunctivitis and OTX-TP for the treatment of glaucoma and
ocular hypertension, the ongoing development of the Company’s injectable
drug delivery depots for back-of-the-eye diseases, the potential utility
of any of the Company’s product candidates, the potential
commercialization of the Company’s product candidates, the Company’s
expectations related to the offering discussed in this press release and
other statements containing the words "anticipate," "believe,"
"estimate," "expect," "intend," "goal," "may," "might," "plan,"
"predict," "project," "target," "potential," "will," "would," "could,"
"should," "continue," and similar expressions, constitute
forward-looking statements within the meaning of The Private Securities
Litigation Reform Act of 1995. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors. Such forward-looking statements involve
substantial risks and uncertainties that could cause the Company’s
clinical development programs, future results, performance or
achievements to differ significantly from those expressed or implied by
the forward-looking statements. Such risks and uncertainties include,
among others, those related to the timing and costs involved in
commercializing ReSure® Sealant or any product candidate that
receives regulatory approval, the initiation and conduct of clinical
trials, availability of data from clinical trials and expectations for
regulatory submissions and approvals, the Company’s scientific approach
and general development progress, the availability or commercial
potential of the Company’s product candidates, the sufficiency of cash
resources and need for additional financing or other actions and other
factors discussed in the “Risk Factors” section contained in the
Company’s current quarterly and annual reports on file with the
Securities and Exchange Commission. In addition, the forward-looking
statements included in this press release represent the Company’s views
as of the date of this release. The Company anticipates that subsequent
events and developments will cause the Company’s views to change.
However, while the Company may elect to update these forward-looking
statements at some point in the future, the Company specifically
disclaims any obligation to do so. These forward-looking statements
should not be relied upon as representing the Company’s views as of any
date subsequent to the date of this release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170123006050/en/
Source: Ocular Therapeutix, Inc.
Investors
Ocular Therapeutix, Inc.
Brad Smith
Chief
Financial Officer
bsmith@ocutx.com
or
Burns
McClellan on behalf of Ocular Therapeutix
Steve Klass, 212-213-0006
sklass@burnsmc.com
or
Media
Medical
Dynamics
Cynthia Sutherland, 646-599-8635
Media Group Director
csutherland@rxmedyn.com
or
Ocular
Therapeutix, Inc.
Scott Corning
Vice President of Marketing &
Commercial Operations
scorning@ocutx.com
